{
    "clinical_study": {
        "@rank": "18480", 
        "acronym": "SARIL-RA-ONE", 
        "arm_group": [
            {
                "arm_group_label": "Sarilumab SAR153191 (REGN88) Dose 1", 
                "arm_group_type": "Experimental", 
                "description": "A single subcutaneous injection of Dose 1 every two weeks."
            }, 
            {
                "arm_group_label": "Sarilumab SAR153191 (REGN88) Dose 2", 
                "arm_group_type": "Experimental", 
                "description": "A single subcutaneous injection of Dose 2 every two weeks."
            }
        ], 
        "brief_summary": {
            "textblock": "Primary Objective:\n\n      To evaluate the immunogenicity of sarilumab administered as monotherapy.\n\n      Secondary Objectives:\n\n        -  To evaluate the other safety aspects of sarilumab administered as monotherapy.\n\n        -  To assess the exposure of sarilumab administered as monotherapy."
        }, 
        "brief_title": "To Evaluate the Immunogenicity and Safety of Sarilumab Administered as Monotherapy in Patients With Rheumatoid Arthritis (RA)", 
        "completion_date": {
            "#text": "August 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Rheumatoid Arthritis", 
        "condition_browse": {
            "mesh_term": [
                "Arthritis", 
                "Arthritis, Rheumatoid"
            ]
        }, 
        "detailed_description": {
            "textblock": "Total study duration is up to 34 weeks: Up to 4-week screening period, 24-week open-label\n      treatment phase, 6-week post-treatment observation. After completion of the treatment phase\n      of this study, patients are eligible to enter a long term safety study (LTS11210 -\n      SARIL-RA-EXTEND) for continuous treatment with sarilumab (SAR153191 [REGN88])."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion criteria:\n\n          -  Diagnosis of rheumatoid arthritis (RA)  \u2265 3 months.\n\n          -  Moderately to severely active rheumatoid arthritis.\n\n          -  Patients who per investigator judgment were incomplete responders to at least 12\n             weeks of an adequate dose of continuous treatment with or who were intolerant of one\n             or a combination of non-biologic disease modifying anti-rheumatic drugs (DMARDs).\n\n        Exclusion criteria:\n\n          -  Patients < 18 years of age.\n\n          -  Past history of, or current, autoimmune or inflammatory systemic or localized joint\n             disease(s) other than RA.\n\n          -  History of juvenile idiopathic arthritis or arthritis onset prior to age 16.\n\n          -  Severe active systemic RA, including but not limited to vasculitis, pulmonary\n             fibrosis, and/or Felty's syndrome.\n\n          -  Prior treatment with any biologic anti-interleukin 6 (IL-6) or IL-6 receptor (IL-6R)\n             antagonist therapies.\n\n          -  Treatment with prednisone > 10 mg or equivalent per day, or change in dosage within 4\n             weeks prior to randomization.\n\n          -  New treatment with or dose-adjustment of on-going nonsteroidal anti-inflammatory drug\n             (NSAIDs) or cyclooxygenase-2 (COX-2) inhibitors within 4 weeks prior to\n             randomization, except for the use of low-dose acetylsalicylic acid for cardiovascular\n             diseases.\n\n          -  Use of parenteral glucocorticoids or intraarticular glucocorticoids injection within\n             4 weeks prior to randomization.\n\n          -  Prior treatment with a Janus kinase (JAK) inhibitor (tofacitinib).\n\n          -  New treatment or dose-adjustment to on-going medication for dyslipidemia, such as\n             statin, within 6 weeks prior to randomization.\n\n          -  Participation in any clinical research study evaluating another investigational drug\n             or therapy within 5 half-lives or 60 days of first dose of study drug administration,\n             whichever is longer.\n\n          -  Patients with a history of malignancy other than adequately-treated carcinoma in-situ\n             of the cervix, nonmetastatic squamous cell or basal cell carcinoma of the skin,\n             within 5 years prior to the randomization visit. Nonmalignant lymphoproliferative\n             disorders are also excluded.\n\n          -  Patients with active tuberculosis or untreated latent tuberculosis infection.\n\n          -  Pregnant or breast feeding women.\n\n        The above information is not intended to contain all considerations relevant to a\n        patient's potential participation in a clinical trial."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "120", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 21, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02121210", 
            "org_study_id": "EFC13752", 
            "secondary_id": [
                "2013-002790-22", 
                "U1111-1143-4344"
            ]
        }, 
        "intervention": {
            "arm_group_label": [
                "Sarilumab SAR153191 (REGN88) Dose 1", 
                "Sarilumab SAR153191 (REGN88) Dose 2"
            ], 
            "description": "Pharmaceutical form:solution Route of administration: subcutaneous", 
            "intervention_name": "sarilumab SAR153191 (REGN88)", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "May 22, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Mesquite", 
                    "country": "United States", 
                    "state": "Texas", 
                    "zip": "75150"
                }, 
                "name": "Investigational Site Number 840074"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "An Open-label, Randomized, Parallel Group Study Assessing the Immunogenicity and Safety of Sarilumab Administered as Monotherapy in Patients With Active Rheumatoid Arthritis", 
        "overall_contact": {
            "email": "Contact-Us@sanofi.com", 
            "last_name": "For site information, send an email with site number to"
        }, 
        "overall_official": {
            "affiliation": "Sanofi", 
            "last_name": "Clinical Sciences & Operations", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "August 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "The incidence of anti-drug antibody (ADA) from baseline", 
            "safety_issue": "Yes", 
            "time_frame": "up to 24 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02121210"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Safety as assessed by adverse events/serious adverse events, vital signs, physical examinations, clinical laboratory, ECGs from baseline", 
                "safety_issue": "Yes", 
                "time_frame": "up to 24 weeks"
            }, 
            {
                "measure": "Sarilumab exposure assessed by pre-dose serum sarilumab concentrations from baseline", 
                "safety_issue": "Yes", 
                "time_frame": "up to 24 weeks"
            }
        ], 
        "source": "Sanofi", 
        "sponsors": {
            "collaborator": {
                "agency": "Regeneron Pharmaceuticals", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Sanofi", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "May 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}